155 related articles for article (PubMed ID: 16531745)
21. High frequency of a retinoid X receptor gamma gene variant in familial combined hyperlipidemia that associates with atherogenic dyslipidemia.
Nohara A; Kawashiri MA; Claudel T; Mizuno M; Tsuchida M; Takata M; Katsuda S; Miwa K; Inazu A; Kuipers F; Kobayashi J; Koizumi J; Yamagishi M; Mabuchi H
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):923-8. PubMed ID: 17272748
[TBL] [Abstract][Full Text] [Related]
22. Variation within the gene encoding the upstream stimulatory factor 1 does not influence susceptibility to type 2 diabetes in samples from populations with replicated evidence of linkage to chromosome 1q.
Zeggini E; Damcott CM; Hanson RL; Karim MA; Rayner NW; Groves CJ; Baier LJ; Hale TC; Hattersley AT; Hitman GA; Hunt SE; Knowler WC; Mitchell BD; Ng MC; O'Connell JR; Pollin TI; Vaxillaire M; Walker M; Wang X; Whittaker P; Xiang K; Jia W; Chan JC; Froguel P; Deloukas P; Shuldiner AR; Elbein SC; McCarthy MI;
Diabetes; 2006 Sep; 55(9):2541-8. PubMed ID: 16936202
[TBL] [Abstract][Full Text] [Related]
23. How should FCHL be defined and how should we think about its metabolic bases?
Sniderman AD; Ribalta J; Castro Cabezas M
Nutr Metab Cardiovasc Dis; 2001 Aug; 11(4):259-73. PubMed ID: 11831111
[No Abstract] [Full Text] [Related]
24. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility.
Martín-Campos JM; Escolà-Gil JC; Ribas V; Blanco-Vaca F
Curr Opin Lipidol; 2004 Jun; 15(3):247-53. PubMed ID: 15166779
[TBL] [Abstract][Full Text] [Related]
25. The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemia.
van der Vleuten GM; Isaacs A; Hijmans A; van Duijn CM; Stalenhoef AF; de Graaf J
J Lipid Res; 2007 Jan; 48(1):193-200. PubMed ID: 17065663
[TBL] [Abstract][Full Text] [Related]
26. Status of "familial combined hyperlipidemia".
Brunzell JD; Motulsky AG
Prog Clin Biol Res; 1984; 147():403-5. PubMed ID: 6739492
[No Abstract] [Full Text] [Related]
27. Pathway analysis detect potential mechanism for familial combined hyperlipidemia.
Wang YL; Xue F; Liu LZ; He ZH
Eur Rev Med Pharmacol Sci; 2013 Jul; 17(14):1909-15. PubMed ID: 23877856
[TBL] [Abstract][Full Text] [Related]
28. Familial combined hyperlipidaemia: how can genetic disorders be common, complex and comprehensible?
Sniderman A; Bailey SD; Engert JC
Clin Sci (Lond); 2007 Nov; 113(9):365-7. PubMed ID: 17608621
[TBL] [Abstract][Full Text] [Related]
29. [Familial combined hyperlipidemia].
de Bruin TW; Dallinga-Thie GM; Erkelens DW
Ned Tijdschr Geneeskd; 1996 Oct; 140(43):2118-21. PubMed ID: 8965962
[No Abstract] [Full Text] [Related]
30. Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting.
Civeira F; Jarauta E; Cenarro A; García-Otín AL; Tejedor D; Zambón D; Mallen M; Ros E; Pocoví M
J Am Coll Cardiol; 2008 Nov; 52(19):1546-53. PubMed ID: 19007590
[TBL] [Abstract][Full Text] [Related]
31. Novel genes for familial combined hyperlipidemia.
Aouizerat BE; Allayee H; Bodnar J; Krass KL; Peltonen L; de Bruin TW; Rotter JI; Lusis AJ
Curr Opin Lipidol; 1999 Apr; 10(2):113-22. PubMed ID: 10327279
[TBL] [Abstract][Full Text] [Related]
32. Combined hyperlipidemia: familial but not (usually) monogenic.
Brahm AJ; Hegele RA
Curr Opin Lipidol; 2016 Apr; 27(2):131-40. PubMed ID: 26709473
[TBL] [Abstract][Full Text] [Related]
33. [Familial combined hyperlipidemia].
Kastelein JJ; ten Cate JW
Ned Tijdschr Geneeskd; 1997 Apr; 141(15):747-8. PubMed ID: 9213793
[No Abstract] [Full Text] [Related]
34. Upstream stimulating factor-1 mediates the E-box-dependent transcriptional repression of the plasminogen activator inhibitor-1 gene in human mast cells.
Ma Z; Jhun B; Oh CK
FEBS Lett; 2007 Sep; 581(23):4485-90. PubMed ID: 17765897
[TBL] [Abstract][Full Text] [Related]
35. The new type 2 diabetes gene TCF7L2.
Florez JC
Curr Opin Clin Nutr Metab Care; 2007 Jul; 10(4):391-6. PubMed ID: 17563454
[TBL] [Abstract][Full Text] [Related]
36. HNF4A genetic variants: role in diabetes.
Love-Gregory L; Permutt MA
Curr Opin Clin Nutr Metab Care; 2007 Jul; 10(4):397-402. PubMed ID: 17563455
[TBL] [Abstract][Full Text] [Related]
37. Longitudinal differences in familial combined hyperlipidemia quantitative trait loci.
Pollex RL; Hegele RA
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):e120. PubMed ID: 16709948
[No Abstract] [Full Text] [Related]
38. Longitudinal differences in familial combined hyperlipidemia quantitative trait loci.
Brouwers MC; Kono N; van Greevenbroek MM; van der Kallen CJ; Lusis AJ; de Bruin TW; Cantor RM
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):e118-9. PubMed ID: 16709947
[No Abstract] [Full Text] [Related]
39. Metabolic syndrome prevalence and characteristics in Greek adults with familial combined hyperlipidemia.
Skoumas J; Papadimitriou L; Pitsavos C; Masoura C; Giotsas N; Chrysohoou C; Toutouza M; Panagiotakos D; Stefanadis C
Metabolism; 2007 Jan; 56(1):135-41. PubMed ID: 17161236
[TBL] [Abstract][Full Text] [Related]
40. Tumor necrosis factor-alpha is a marker of familial combined hyperlipidemia, independently of metabolic syndrome.
Pauciullo P; Gentile M; Marotta G; Baiano A; Ubaldi S; Jossa F; Iannuzzo G; Faccenda F; Panico S; Rubba P
Metabolism; 2008 Apr; 57(4):563-8. PubMed ID: 18328361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
